


General approach to the synthesis of optically active 2-carboxy-4-[3'-(diethoxyphosphinyl)propyl]-5-alkylpiperazines (CPP analogues)

Massimo Falorni,* Andrea Porcheddu and Giampaolo Giacomelli


Dipartimento di Chimica, Università di Sassari, Via Vienna 2, I-07100 Sassari, Italy

Abstract: General stereospecific syntheses of the optically active title compounds are described. The procedures presented are based on readily available starting materials, such as piperazine alcohols, and can be arranged for multigram quantities. © 1997 Elsevier Science Ltd

The pharmacological action of the excitatory amino acids (EAA), L-glutamate and L-aspartate, is well documented.¹ In this context, 2-carboxy-4-(3-phosphonopropyl) piperazine (CPP) has been identified as a potent and selective antagonist of the *N*-methyl-D-aspartate (NMDA) subtype of the glutamate receptor.² Recently we have published³ the first stereocontrolled synthesis of (*R*)-CPP starting from *cyclo*-Sar-Ser; following our interest in the field of NMDA antagonists we have carried out the preparation of 5-alkyl substituted CPP-analogues **1** and **2**.



A reliable retrosynthetic analysis for **1** and **2** suggested a correlation between the diastereomerically defined precursor, 2-carboxy-5-alkyl-4-[3'-(diethoxyphosphinyl)propyl]-piperazine, and 2-hydroxymethyl piperazine, that can be prepared by reduction of serine-containing diketopiperazine (Scheme 1). The availability of enantiomers of both the amino acids should enable the preparation of all the four possible stereoisomers.




Scheme 1.

For a synthesis that could be applied on a multigram scale and follows also the rule of atom economy, the main problem is the differentiation of the two nitrogen atoms in the piperazine ring. The presence of the hydroxy group in the piperazine alcohols suggested the use of *N,O*-acetals as a protection and differentiation of the nitrogen atom in the 1-position of the heterocyclic ring. After this step, the oxazolidine ring should be removed and the hydroxymethyl group oxidised after the preliminary protection of the *N*(1) atom and the quaternization of the *N*(4) atom. The complete synthesis of **1** (*R*=*i*-

* Corresponding author. Email: fmax@ssmain.uniss.it


Pr) and **2** (R=*i*-Bu) is presented here as a representative example. However, the procedures reported can be applied to 5-alkyl-2-hydroxymethyl piperazines as general method.

After a first attempt to prepare the *N,O*-acetonide derivatives of the aminoalcohols **3a–b**, we preferred to employ PhCHO owing to the better stability of *N,O*-benzylidene acetal ring and to minimize the formation of byproduct (Scheme 2). Thus, the treatment of **3a** and **3b** with freshly distilled PhCHO in the presence of 5 Å molecular sieves in benzene at reflux for 30 min afforded the oxazolidines **4a–b** in high yields after bulb to bulb distillation. Concerning the structures **4a–b**, NOE experiments confirmed the presence of the oxazolidine ring involving the *N*(1) atom, thus excluding the formation of a six membered ring involving *N*(4) atom. As shown by the GLC and ¹H NMR analysis, the products **4a–b** are a mixture of two epimers at C(9) in 85/15 ratio for **4a** and in 55/45 ratio for **4b**. The alkylation at *N*(4) atom was carried out using Br(CH₂)₃PO(OEt)₂ in the presence of Na₂CO₃ in various solvents: best results were obtained using refluxing MeOH. After 24 h, the alkylphosphonates **5a** and **5b** were recovered in 65–78% yield after chromatographic purification. In the subsequent step, the *N,O*-acetal ring was removed by acid hydrolysis with 10% aq HCl at room temperature overnight.



Scheme 2.


Treatment of **5a** with (Boc)₂O and Na₂CO₃ in presence of catalytic NH₂OH in CH₂Cl₂/H₂O gave, in quantitative yield, the *N*-Boc derivative (2*S*,5*S*)-**6a**. When the same treatment was applied to 2-hydroxymethyl piperazines, having the (2*R*,5*S*) configuration, the reactions afforded the *N*-Boc derivatives in very low yields. Other methodologies for Boc-group introduction did not give satisfactory results. The use of the ethoxycarbonyl group, less hindered than Boc-group, for protecting the *N*(1) atom, allowed us to overcome this problem. Thus, the treatment of **2c** with ClCOOEt, in benzene at 0°C for 1 h, afforded the **6b** compound in 59% yield (Scheme 3).



Reagents and conditions: iv) Boc₂O, CH₂Cl₂/H₂O, Na₂CO₃, NH₂OH (cat), rt, 8 h. v) ClCOOEt, benzene 0° C, 1 h

Scheme 3.

The ammonium salts **7a** and **7b** were obtained by adding MeI to the *N*(1)-protected aminoalcohols **6a** and **6b** at r.t. in MeOH, for 24–48 h. Then the crude products were dissolved in water and washed with CH₂Cl₂ affording the pure ammonium salts that were isolated in 83–94% yield respectively (Scheme 4).



Scheme 4.

The compounds **7a** and **7b** were then oxidised following the Sharpless procedure⁴ with sodium periodate in the presence of catalytic amounts of RuCl₃.⁵ The oxidation mixtures were filtered on Celite pad, affording, after removal of inorganic salts, the crude acids **8a-b** in 65–88% yield, as light brown foams. The structures of acids **8a-b** were confirmed by ¹H NMR analysis and by elementary analysis. Attempts to carry out the demethylation of these crude acids using PhSNa⁶ were however unsuccessful. Thus, demethylation was achieved by using the acetate anion as nucleophile: the crude oxidation products were then lyophilised from acetic acid solutions affording the acetates. Heating at 140°C for 72 h of the acetates in xylene/acetonitrile as solvent afforded the corresponding demethylated amino acids, which were recovered in satisfactory yields from the reaction mixture as methyl esters **9a** and **9b**, by treatment with HCl in MeOH at rt.⁷ Measurements of ¹H and ¹³C NMR spectra carried out at various temperatures (from 20° to 50°C) have indicated that both compounds **9a** and **9b** have a diastereoisomeric purity ≥97%. Subsequent treatment with 6 N HCl (reflux, 12 h) restored the phosphonic acid moiety and removed the *N*(1) protecting group. However, the recovery of **1** or **2** as free amino acids by using ion exchange chromatography gave poor results, the target compounds being recovered only in small quantities.⁸

Experimental section

Melting and boiling points are uncorrected. Bulb to bulb distillations were carried out with a Büchi GRK-51 apparatus equipped with a vacuum controller Büchi B-168. Elemental analyses were performed on a Perkin–Elmer 420 B analyzer. Optical rotations were measured with a Perkin–Elmer 241 automatic polarimeter in a 1 dm tube. GC analyses of the reaction products were carried out on a Perkin–Elmer 8600 gas-chromatograph on fused silica megabore columns (15 m × 0.53 mm) DB-1, DB-5 (J&W), operating with a He flow rate of 9 mL/min. The ¹H NMR (300 MHz), ¹³C NMR (75.4 MHz) and ³¹P (121.4 MHz) Fourier transform spectra were obtained with a Varian VXR-300 spectrometer on CDCl₃ solutions (unless otherwise specified). All reactions involving air sensitive materials were carried out under argon atmosphere; all reagents and solvents employed were reagent grade materials purified by standard methods and distilled before use. (2*S*,5*S*)-2-Hydroxymethyl-5-*iso*-propylpiperazine, **3a**, [α]_D²⁵ +5.61 (c 1, CHCl₃), and (2*R*,5*S*)-2-hydroxymethyl-5-*iso*-butylpiperazine, **3b**, [α]_D²⁵ +4.9 (c 9, CHCl₃) were prepared as previously reported.⁹

General procedure for **4a** and **4b**

A solution of 5-alkyl-2-hydroxymethylpiperazine **3a** and **3b** (11.4 mmol) and freshly distilled benzaldehyde (12.5 mmol) in dry benzene (40 mL) was placed in a 100 mL two-necked-flask and heated at reflux in presence of activated molecular sieves (5 Å), under N₂ atmosphere. After 1 h the mixture was concentrated at reduced pressure (20 mBar) and the crude product bulb to bulb distilled (150°C) to give pure (GLC) protected piperazine **4a** and **4b**.

(3*S*,6*S*,9*RS*)-9-Phenyl-3-iso-propyl-1,4-diaza-8-oxa[4.3.0.]bicyclononane 4a

94%, colourless oil. ^1H NMR δ : 85/15 mixture of two diastereoisomers, 7.48–7.41 (m, 2H, Ph), 7.39–7.24 (m, 3H, Ph), 5.51 (s, 0.15H, PhCH), 4.60 (s, 0.85H, PhCH), 4.24 (t like, 0.15H, NCHCH₂O), 4.05 (t like, 0.85H, NCHCH₂O), 3.66 (dd like, 1H, NCHCH₂O), 3.22 (dd like, 1H), 2.72 (t like, 1H), 2.68 (dd like, 1H), 2.63–2.52 (m, 1H), 2.50–2.43 (m, 1H), 1.88 (t like, 1H), 1.60–1.46 [m, 1H, CH(CH₃)₂], 1.40 (bs, 1H, NH), 0.95 [d, 3H, $J=6$, CH(CH₃)₂], 0.85 ppm [d, 3H, $J=6$, CH(CH₃)₂]. ^{13}C NMR δ : 138.7, 129.0, 128.2, 127.4, 96.3, 69.4, 68.6, 62.3, 60.1, 56.7, 56.4, 50.7, 48.0, 47.4, 31.4, 19.1 ppm. Calculated for C₁₅H₂₂N₂O: C, 73.13; H, 9.0; N, 11.37. Found: C, 73.0; H, 8.93; N, 11.41.

(3*S*,6*R*,9*RS*)-9-Phenyl-3-iso-butyl-1,4-diaza-8-oxa[4.3.0.]bicyclononane 4b

72%, colourless oil. ^1H NMR δ : 55/45 mixture of two diastereoisomers, 7.50–7.41 (m, 2H, Ph), 7.39–7.29 (m, 3H, Ph), 5.57 (s, 0.55H, PhCH), 5.20 (s, 0.45H, PhCH), 3.98–3.79 (m, 2H, NCHCH₂O), 3.25–3.15 (m, 1H), 3.10–2.91 (m, 2H), 2.91–2.82 (m, 1H), 2.50 (t like, 1H), 2.22–2.10 (m, 1H), 1.80 (bs, 1H, NH), 1.75–1.65 [m, 1H, CH₂CH(CH₃)₂], 1.42–1.11 [m, 2H, CH₂CH(CH₃)₂], 0.92 [d, 3H, $J=6$, CH₂CH(CH₃)₂], 0.83 ppm [d, 3H, $J=6$, CH₂CH(CH₃)₂]. ^{13}C NMR δ : 136.8, 128.5, 127.6, 126.0, 99.0, 96.4, 90.2, 65.8, 63.8, 60.2, 55.6, 54.0, 51.0, 49.6, 43.7, 42.0, 24.5, 24.3, 23.2, 22.5, 22.2 ppm. Calculated for C₁₆H₂₄N₂O: C, 73.81; H, 9.29; N, 10.76. Found: C, 73.90; H, 9.11; N, 10.37.

General procedure for 5a and 5b

Protected piperazines **4a** and **4b** (6.1 mmol) were dissolved in absolute methanol (50 mL) and sodium carbonate (9.4 mmol) and diethyl (bromopropyl) phosphonate (12.5 mmol) were added. The reaction was refluxed for 24 h under N₂ atmosphere. After filtration, the methanol solution was concentrated under reduced pressure. The brown oil residue was placed on a silica gel column and eluted with AcOEt/CH₂Cl₂/MeOH 7/1/2. The crude compound was dissolved in 10% aq HCl (30 mL) and stirred at r.t. for 12 h. Then, the aqueous solution was made alkaline with KOH and extracted with CH₂Cl₂ several times. The collected organic phases were dried (Na₂SO₄) and the solvent eliminated under vacuum affording pure (TLC: AcOEt/CH₂Cl₂ 7/3) *N*-alkylated piperazine methanols **5a** and **5b**.

(2*S*,5*S*)-2-Hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-propylpiperazine 5a

65%; $[\alpha]_{\text{D}}^{25}$ +21.8 (c 0.6, CHCl₃); ^1H NMR δ : 4.19–4.00 [m, 4H, P(OCH₂CH₃)₂], 3.85 (dd, 1H, $J_1=11$, $J_2=3$, CH₂OH), 3.41 (dd, 1H, $J_1=11$, $J_2=5$, CH₂OH), 2.95–2.66 (m, 4H), 2.38–2.25 (m, 2H), 2.24–2.12 (m, 2H), 2.10–1.99 (m, 1H), 1.98–1.88 (m, 1H), 1.80–1.62 (m, 5H), 1.25 [t, 6H, $J=7$, P(OCH₂CH₃)₂], 0.86 [d, 3H, $J=7$, CH(CH₃)₂], 7.76 ppm [d, 3H, $J=7$, CH(CH₃)₂]; ^{13}C NMR δ : 64.1, 61.3, 59.9, 54.9, 52.6, 50.3, 47.0, 26.3, 24.4, 22.5, 19.8, 19.1, 16.3 ppm; ^{31}P NMR δ : 32.9 ppm. Calculated for C₁₅H₃₃N₂O₄P: C, 53.56; H, 9.89; N, 8.33. Found: C, 53.57; H, 9.85; N, 8.36.

(2*R*,5*S*)-2-Hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-propylpiperazine 5b

78%; $[\alpha]_{\text{D}}^{25}$ +27.8 (c 2.5, CHCl₃); ^1H NMR δ : 4.15–4.02 [m, 5H, P(OCH₂CH₃)₂+CH₂OH], 3.90–3.81 (dd like, 1H, CH₂OH), 3.65–3.43 (m, 2H), 2.72–2.60 (m, 2H), 2.58–2.37 (m, 4H), 2.38–2.30 (m, 1H), 1.80–1.62 (m, 5H), 1.55–1.40 [m, 2H, CH₂CH(CH₃)₂], 1.25–1.16 [m, 1H, CH(CH₃)₂], 1.28 [t, $J=7$, 6H, P(OCH₂CH₃)₂], 0.89 [d, $J=7$, 3H, CH(CH₃)₂], 0.80 ppm [d, $J=7$, 3H, (CH₃)₂]; ^{13}C NMR δ : 71.2, 65.9, 65.6, 59.7, 58.5, 57.5, 52.7, 52.2, 45.8, 25.5, 24.1, 22.8, 19.8, 16.6 ppm; ^{31}P NMR δ : 34.1 ppm. Calculated for C₁₆H₃₅N₂O₄P: C, 54.84; H, 10.07; N, 7.99. Found: C, 54.8; H, 10.1; N, 8.03.

(2*S*, 5*S*)-1-(tert-Butoxycarbonyl)-2-hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-propylpiperazine 6a

A solution of compound **5a** (1.0 g, 3.0 mmol) in CH₂Cl₂ (15 mL), solid Boc₂O (0.65 g, 3.0 mmol), Na₂CO₃ (0.6 g, 5.7 mmol) and NH₂OH·HCl (10% mol) in H₂O (15 mL) were mixed together and stirred for 48 h at r.t. The organic and aqueous layers were separated and the aqueous layer extracted with CH₂Cl₂ (20 mL). The combined organic phases were washed with H₂O, dried (Na₂SO₄)

then evaporated under reduced pressure. The crude product was purified by flash chromatography (AcOEt/CH₂Cl₂ 2/8) to furnish the protected **6a** (1.25 g, 97%) having: $[\alpha]_D^{25} -1.65$ (c 3.25, CHCl₃); ¹H NMR δ : 4.0–3.85 [m, 4H, P(OCH₂CH₃)₂], 3.81 (dd, $J_1=14$, $J_2=8$, 1H, CH₂OH), 2.82 (dd, $J_1=14$, $J_2=4$, 1H, CH₂OH), 2.65–2.55 (m, 3H), 2.42–2.35 (m, 1H), 2.28–2.10 (m, 2H), 2.05–1.09 (mb, 3H), 1.65–1.40 (m, 5H), 1.34 [s, 9H, C(CH₃)₃], 1.19 [t, 6H, $J=7$, P(OCH₂CH₃)₂], 0.78 [d, $J=7$, 3H, CH(CH₃)₂], 0.72 ppm [d, $J=7$, 3H, CH(CH₃)₂]; ¹³C NMR δ : (mixture of two conformers) 155.4, 81.7, 66.7, 63.4, 61.1, 61.0, 58.1, 55.0, 53.9, 53.6, 52.0, 51.7, 50.5, 27.4, 25.9, 24.0, 23.9, 22.2, 22.1, 19.6, 18.3, 18.2, 17.9, 17.8, 16.2, 16.1 ppm. Calculated for C₂₀H₄₁N₂O₆P: C, 55.86; H, 9.92; N, 6.2. Found: C, 55.93; H, 10.03; N, 6.31.

(2R,5S)-1-Ethoxycarbonyl-2-hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-butylpiperazine 6b

To a solution of amino alcohol **5b** (1 g, 2.8 mmol) and NEt₃ (0.4 g, 3.9 mmol), in dry benzene, ClCOOEt (0.3 g, 2.8 mmol) was added at 0°C under N₂. The mixture was stirred at 0°C for 1 h then at r.t. for an additional hour. The white solid formed was filtered off and the resulting solution washed with 10% aq. HCl (3×10 mL). The aqueous solutions were made alkaline with solid KOH, saturated with NaCl and extracted with CH₂Cl₂ several times. The collected organic phases were dried (Na₂SO₄) and the solvent was eliminated under vacuum affording the product **6b** (0.7 g, 59%), pure (TLC, AcOEt/MeOH 85/15) having: $[\alpha]_D^{25} +83.01$ (c 3.95, CHCl₃), ¹H NMR δ 4.15–3.98 (m, 8H), 3.88–3.80 (m, 2H), 3.08 (d like, 1H), 2.85–2.72 (m, 2H), 2.38–2.24 (m, 1H), 2.23–2.08 (m, 2H), 1.85–1.53 (m, 5H), 1.50–1.37 (m, 1H) 1.30 [t, 7H, $J=7$, P(OCH₂CH₃)₂+CH₂CH(CH₃)₂], 1.23 (t, 3H, $J=7$, COOCH₂CH₃), 1.12–1.01 [m, 1H, CH(CH₃)₂], 0.89 [d, 3H, CH(CH₃)₂] 0.86 ppm [d, 3H, $J=7$, CH(CH₃)₂]; ¹³C NMR δ : 155.8, 64.4, 63.7, 61.4, 61.3, 58.2, 56.2, 52.7, 52.3, 51.5, 46.0, 40.2, 25.0, 23.8, 21.8 19.1 16.4 ppm. Calculated for C₁₉H₃₉N₂O₆P: C, 54.0; H, 9.31; N, 6.63. Found: C, 53.90; H, 9.40; N, 6.60.

(2S,5S)-1-(tert-Butoxycarbonyl)-2-hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-4-methyl-5-iso-propyl piperazinium iodide 7a

Methyl iodide (2 mL, 21 mmol) was added to the protected derivatives **6a** (1.0 g, 2.3 mmol) in MeOH (20 mL). After 18 h under stirring, all the volatile products were eliminated under reduced pressure and the residues partitioned between CH₂Cl₂ and H₂O. The organic layers were discarded and the aqueous phases concentrated under vacuum affording pure (TLC) ammonium salt **7a**: (1.1 g, 83%), $[\alpha]_D^{25} +65.3$ (c 1.35, CH₃COOH); ¹H NMR (D₂O) δ : 4.13–4.00 [m, 6H, P(OCH₂CH₃)₂+CH₂OH], 3.82 (dd like, 2H), 3.22 (s, 1.2H, N–Me), 2.90 (s, 1.8H, N–Me), 2.90–2.70 (m, 2H), 2.60–2.40 (m, 1H), 2.30–2.10 (m, 1H), 1.88–1.60 (m, 4H), 1.35 (m, 3H), 1.26 [s, 9H, C(CH₃)₃], 1.11 [t, 6H, $J=7$, P(OCH₂CH₃)₂], 0.89 [d, $J=7$, 3H, CH(CH₃)₂], 0.75 ppm [d, $J=7$, 3H, CH(CH₃)₂]; ¹³C NMR (D₂O) δ : 146.8, 79.3, 67.6, 61.5, 61.4, 61.1, 59.8, 58.0, 56.2, 46.2, 46.0, 25.0, 23.8, 19.1, 18.9, 16.4, 16.0, 17.2, 16.3 ppm. Calculated for C₂₁H₄₄N₂O₆PI: C, 43.60; H, 7.67; N, 4.84. Found: C, 43.3; H, 7.65; N, 4.88.

(2R,5S)-1-Ethoxycarbonyl-2-hydroxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-4-methyl-5-iso-butyl piperazinium iodide 7b

Methyl iodide (4 mL, 42 mmol) was added to the protected derivatives **6b** (0.65 g, 1.5 mmol) in MeOH (20 mL). After 48 h the reaction was worked up as previously described for **7a** to afford pure (TLC) ammonium salt **7b**: (0.8 g, 94%), $[\alpha]_D^{25} +52.4$ (c 2.5, CH₃COOH); ¹H NMR (D₂O) δ : 4.11–3.94 [m, 8H, P(OCH₂CH₃)₂+OCH₂CH₃+CH₂OH], 3.86–3.60 (m, 3H), 3.55–3.38 (m, 3H), 3.35–3.20 (m, 2H), 3.06 (s, 1.3H, N–Me), 2.95 (s, 1.7H, N–Me), 2.05–1.75 (m, 3H), 1.70–1.58 (m, 2H), 1.49–1.32 (m, 2H), 1.19 [t, 6H, $J=7$, P(OCH₂CH₃)₂], 1.12 (t, 3H, $J=7$, OCH₂CH₃) 0.87 [d, 3H, $J=7$, CH(CH₃)₂], 0.84 ppm [d, 3H, $J=7$, CH(CH₃)₂]; ¹³C NMR (D₂O) δ : 152.0, 77.3, 68.6, 68.0, 59.7, 59.4, 49.2, 48.4, 48.1, 42.7, 34.2, 34.1, 31.7, 29.3, 29.1, 24.7, 24.6, 24.5 ppm. Calculated for C₂₀H₄₂N₂O₆PI: C, 42.56; H, 7.5; N, 4.96. Found: C, 42.48; H, 7.41; N, 5.01.

(2S,5S)-1-(tert-Butoxycarbonyl)-2-carboxy-4-[3'-(diethoxyphosphinyl)propyl]-4-methyl-5-iso-propyl piperazinium 8a

Under stirring at 0°C, NaIO₄ (3.5 g, 11 mmol) in water (40 mL) and RuCl₃ hydrate (0.08 g) were added to ammonium salt **7a** (1 g, 1.7 mmol) in acetone (60 mL). The reaction mixture was stirred for 1 h at 0°C and for an additional hour at r.t., then quenched with *iso*-propanol (4 mL). After 2 h, the reaction mixture was filtered through a Celite pad and the filtrate concentrated under vacuum. The residue was dissolved in H₂O (10 mL) and washed with CCl₄ (2×20 mL) and CH₂Cl₂ (2×25 mL), then the organic phase was discarded and the aqueous solution evaporated to give **8a** (0.65 g, 82%), [α]_D²⁵ +43.21 (c 1.35, CH₃COOH); ¹H NMR (D₂O) δ : 4.1–3.9 [m, 4H, P(OCH₂CH₃)₂], 3.3–3.5 (m, 3H), 2.3–2.4 (m, 3H), 2.1 (s, 1.6H, N–CH₃), 2.3–2.1 (m, 3H), 1.8 (s, 1.4H, N–CH₃), 1.6–1.4 (m, 3H), 1.33 [s, 9H, C(CH₃)₃], 1.12–1.15 [t, *J*=7, 6H, PO(CH₂CH₃)₂], 0.84 [d, *J*=7, 3H, CH(CH₃)₂], 0.80 ppm [d, *J*=7, 3H, CH(CH₃)₂]; ¹³C NMR (D₂O) δ : 185.9, 148.6, 75.8, 72.1, 63.0, 55.3, 49.2, 41.5, 37.9, 36.7, 32.1, 30.3, 28.3, 28.5, 25.6, 25.4, 24.1, 22.6, 21.5 ppm; Calculated for C₂₁H₄₁N₂O₇P: C, 54.3; H, 8.9; N, 6.03. Found: C, 54.22; H, 9.01; N, 6.1.

(2R,5S)-1-(Ethoxycarbonyl)-2-carboxy-4-[3'-(diethoxyphosphinyl)propyl]-4-methyl-5-iso-butyl piperazinium 8b

Under stirring at 0°C, NaIO₄ (4.6 g, 11 mmol) in water (40 mL) and RuCl₃ hydrate (0.08 g) were added to ammonium salt **7b** (1.2 g, 2.2 mmol) in acetone (60 mL). The reaction was worked up as previously described for **8a** to afford to give **8b** (0.60 g, 59%), [α]_D²⁵ +24.1 (c 1.27, CH₃COOH); ¹H NMR (D₂O) δ : 4.12–3.91 [m, 8H, P(OCH₂CH₃)₂+OCH₂CH₃+CH₂OH], 3.50–3.34 (m, 2H), 3.30–3.13 (m, 2H), 3.08–2.99 (m, 1H), 2.98 (s, 1.5H, N–CH₃), 2.75 (s, 1.5H, N–CH₃), 2.06–1.73 (m, 4H), 1.64–1.43 (m, 2H), 1.42–1.24 (m, 1H), 1.17 [t, *J*=7, 6H, PO(CH₂CH₃)₂], 1.05 (t, *J*=7, 3H, OCH₂CH₃), 0.83 [d, *J*=7, 3H, CH(CH₃)₂], 0.80 ppm [d, *J*=7, 3H, CH(CH₃)₂]; ¹³C NMR (D₂O) δ : 165.2, 151.9, 80.7, 68.4, 66.9, 61.2, 60.2, 58.5, 49.2, 48.3, 42.0, 33.8, 31.2, 30.0, 28.5, 24.3, 23.6, 22.2 ppm; Calculated for C₂₀H₃₉N₂O₇P: C, 53.3; H, 8.73; N, 6.22. Found: C, 53.28; H, 8.80; N, 6.31.

(2S,5S)-2-Carboxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-propylpiperazine 9a

The crude acid **8a** (0.34 g, 0.8 mmol) was treated with glacial acetic acid (0.05 g, 0.82 mmol). After 3 h the acetic solution were lyophilised affording pure (TLC) protected acetate (0.38 g, 0.78 mmol). The acetate (0.05 g, 0.78 mmol) was suspended in xylene/acetonitrile (85/15, 100 mL) and heated, under stirring, at 140°C. After 26 h, the reaction mixture was evaporated under vacuum and the residue treated with H₂O and extracted with Et₂O (2×10 mL). The organic phase was discarded and the aqueous layers recovered and evaporated under vacuum. The residue was dissolved in dry MeOH and gaseous HCl was added after 24 h at room temperature: the reaction mixture was reduced to half of the volume and treated with ion exchange resin (OH[−] form) until pH 8–9. The resin was partitioned between CH₂Cl₂ (2×10 mL) and H₂O (2×10 mL), the organic phase then dried (Na₂SO₄) and the solvent eliminated under vacuum affording pure (TLC) methylesters **9a** (0.10 g, 39%): [α]_D²⁵ +5.6 (c 1.53, CH₃COOH); ¹H NMR (DMSO-*d*₆) δ : 4.12–4.00 [m, 4H, P(OCH₂CH₃)₂], 3.86 (s, 3H, OCH₃), 3.65 (dd, 1H, *J*₁=9, *J*₂=3, CHCOOCH₃), 3.41–3.19 (m, 3H), 2.73–2.51 (m, 4H), 2.30 (bs, 1H, NH), 2.15–1.85 (m, 4H), 1.52–1.37 [m, 1H, CH(CH₃)₂], 1.16 [t, 6H, *J*=7, PO(CH₂CH₃)₂], 0.89 [d, *J*=7, 3H, CH(CH₃)₂], 0.85 ppm [d, *J*=7, 3H, CH(CH₃)₂]; ¹³C NMR δ : 172.0, 64.9, 64.7, 63.5, 62.3, 56.0, 52.6, 50.4, 30.7, 23.6, 20.0, 19.3, 17.0, 16.3 ppm. Calculated for C₁₆H₃₃N₂O₅P: C, 52.70; H, 9.13; N, 7.69. Found: C, 52.50; H, 9.21; N, 7.63.

(2R,5S)-2-Carboxymethyl-4-[3'-(diethoxyphosphinyl)propyl]-5-iso-butyl piperazine 9b

As previously described for **9a**, from the crude acid **8b** (0.59 g, 1.3 mmol) pure (TLC) methylesters **9b** was recovered, (0.29 g, 61%); [α]_D²⁵ +2.7 (c 1, CH₃COOH); ¹H NMR (DMSO-*d*₆) δ : 4.21–4.01 [m, 4H, P(OCH₂CH₃)₂], 3.80 (s, 3H, OCH₃), 3.55 (dd, 1H, *J*₁=9, *J*₂=3, CHCOOCH₃), 3.32–3.13 (m, 3H), 2.83–2.59 (m, 4H), 2.42 (bs, 1H, NH), 2.20–1.90 (m, 4H), 1.64–1.43 [m, 3H, CH₂CH(CH₃)₂],

1.04 [t, 6H, PO(CH₂CH₃)₂], 0.83 [d, *J*=7, 3H, CH(CH₃)₂], 0.80 ppm [d, *J*=7, 3H, CH(CH₃)₂]; ¹³C NMR (DMSO-d₆) δ: 175.2, 66.2, 63.5, 61.9, 55.8, 55.5, 54.8, 54.0, 50.0, 45.9, 23.7, 22.3, 21.6, 20.0, 19.2 ppm. Calculated for C₁₇H₃₅N₂O₅P: C, 53.95; H, 9.32; N, 7.40. Found: C, 54.11; H, 9.23; N, 7.37.

Acknowledgements

We thank the Ministero dell'Università e della Ricerca Scientifica e Tecnologica, Roma and the CNR, Roma, for the financial support.

References

1. See for examples: Johnson, R.L.; Koerner, J.F., *J. Med. Chem.*, **1988**, *31*, 2057–2066. Hashimoto, K.; Shirahama, H., *Tetrahedron Lett.*, **1991**, *32*, 2625–2628.
2. Hays, S.J.; Bigge, C.F.; Novak, P.M.; Drummond, J.T.; Bobovski, T.P.; Rice, M.J.; Johnson, G.; Brahce, L.J.; Coughenour, L.L., *J. Med. Chem.*, **1990**, *33*, 2916–2924.
3. Falorni, M.; Porcheddu, A.; Giacomelli, G., *Tetrahedron: Asymmetry*, **1996**, *7*, 1999–2005.
4. Carlsen, H.J.; Katsuki, T.; Martin, V.S.; Sharpless K.B. *J. Org. Chem.*, **1981**, *46*, 3936.
5. The use of RuO₂ instead of RuCl₃ as catalyst causes the oxidative decomposition of the substrates.
6. Shamma, M.; Deno, N.C.; Remar, J.F. *Tetrahedron Lett.*, **1966**, 1375.
7. Wilson, N.D.V.; Joule, J.A. *Tetrahedron*, **1968**, *24*, 5493–5497.
8. A sample of compound **1** could be recovered: ¹H NMR (D₂O): δ: 4.12 (dd, *J*₁=9, *J*₂=3, 1H, CHCOOH), 3.8–4.00 (m, 2H), 3.4–3.7 (m, 2H), 3.34 (t, 2H, CH₂CH₂CH₂P), 2.34 (m, 1H), 2.02 (m, 2H, CH₂CH₂P), 1.68 (m, 2H, CH₂P), 1.5–1.3 [m, 1H, CH(CH₃)₂], 0.88 [d, *J*=7, 3H, CH(CH₃)₂], 0.83 ppm [d, *J*=7, 3H, CH(CH₃)₂].
9. Falorni, M.; Satta, M.; Conti, S.; Giacomelli, G. *Tetrahedron: Asymmetry* **1993**, *4*, 2389–2398.

(Received in UK 19 March 1997)